Drug Type Small molecule drug |
Synonyms CB-1400, NSC-347901, RP 35972 + [1] |
Target |
Mechanism Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC8H6N2S3 |
InChIKeyCKNAQFVBEHDJQV-UHFFFAOYSA-N |
CAS Registry64224-21-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 3 | KR | 01 Feb 2014 | |
Metabolic dysfunction-associated steatotic liver disease | Phase 3 | KR | 01 Feb 2014 | |
Nonalcoholic Steatohepatitis | Phase 3 | - | - | |
Nonalcoholic Steatohepatitis | Phase 3 | - | - | |
Nonalcoholic Steatohepatitis | Phase 3 | - | - | |
Colonic Cancer | Preclinical | US | 01 Apr 2004 |
Phase 2 | 60 | Placebo | rffagrprak(lmmguvktrs) = xlhsabnhfu judjmqflhg (hkinnlsecf ) View more | - | 01 Apr 2017 | ||
rffagrprak(lmmguvktrs) = bqamjijjsy judjmqflhg (hkinnlsecf ) |